PBS pH7.4
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 | 推荐种属 |
---|---|---|
FCM | 1:2000 | Rt |
CD161, also known as KLRB1 or NKRP1A, is a C-type lectin-like receptor primarily expressed on the surface of natural killer (NK) cells and a subset of T cells, including mucosal-associated invariant T (MAIT) cells and some CD8+ T cells. It is particularly enriched in immune cells located in mucosal sites such as the gut and liver. CD161 binds to its ligand, lectin-like transcript 1 (LLT1, also known as CLEC2D), and this interaction can have both inhibitory and costimulatory effects on immune cells. In the context of cancer immunotherapy, CD161 has been identified as a potential inhibitory receptor in glioma-infiltrating T cells. Its activation by CLEC2D on tumor or immunosuppressive cells can dampen T cell responses against cancer cells. Recent studies suggest that blocking the CD161-CLEC2D interaction may enhance T cell-mediated antitumor activity, making CD161 a promising target for cancer immunotherapy.
Flow cytometric analysis of SD Rat splenocytes labelling Rat CD161 antibody at 1/2000 (0.1 μg) dilution/ (Right panel) compared with a Mouse IgG1, κ Isotype Control / (Left panel). Goat Anti-Mouse IgG Alexa Fluor® 488 was used as the secondary antibody. Then cells were stained with CD3 - Brilliant Violet 605™ Antibody separately.